Year All202620252024202320222021202020192018201720162014201320112010 March 20, 2021 Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021 March 9, 2021 Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ENDO 2021 March 1, 2021 Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results February 24, 2021 Rhythm Pharmaceuticals to Present at Cowen & Co. 41st Annual Health Care Conference February 10, 2021 Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares February 4, 2021 Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering February 3, 2021 Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering January 26, 2021 Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities January 19, 2021 Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts January 5, 2021 Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M
March 20, 2021 Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021
February 24, 2021 Rhythm Pharmaceuticals to Present at Cowen & Co. 41st Annual Health Care Conference
February 10, 2021 Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 26, 2021 Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities
January 19, 2021 Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts
